Agilent Technologies, Inc. (A)
| Previous Close | 152.67 |
| Open | 152.52 |
| Bid | 152.00 x 1000 |
| Ask | 170.00 x 1200 |
| Day's Range | 152.02 - 153.60 |
| 52 Week Range | 94.53 - 153.60 |
| Volume | 2,310,071 |
| Avg. Volume | 1,683,773 |
| Market Cap | 46.689B |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | 59.00 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.78 (0.52%) |
| Ex-Dividend Date | Jul. 02, 2021 |
| 1y Target Est | N/A |
- Business Wire
Agilent Early Career Professor Award Presented to Jason H. Yang
SANTA CLARA, Calif., July 28, 2021--Agilent Technologies Inc. (NYSE: A) today announced that Jason H. Yang, Ph.D., has received the 2021 Agilent Early Career Professor Award. Dr. Yang is an assistant professor of Microbiology, Biochemistry and Molecular Genetics in the Center for Emerging and Re-Emerging Pathogens at Rutgers New Jersey Medical School. This year’s award focus was contributions to the development of breakthrough solutions to understand or manage immunological responses to infectio
- Business Wire
Clinical Utility of ALK Fusion Detection by Liquid Biopsy
SANTA CLARA, Calif., July 27, 2021--Agilent Technologies Inc. (NYSE: A) today announced the publication of a paper in the journal Lung Cancer, titled "Clinical Utility of Next-Generation Sequencing-Based ctDNA Testing for Common and Novel ALK Fusions". The study, jointly published by Resolution Bioscience (now a part of Agilent) and Memorial Sloan Kettering Cancer Center (MSK), describes the use of plasma ctDNA NGS to detect novel anaplastic lymphoma kinase (ALK) fusions, and to serially monitor
- Business Wire
Agilent Technologies Celebrates More than 20 Years of Sustainable Progress
SANTA CLARA, Calif., July 22, 2021--Agilent issues 2020 corporate social responsibility report.
